Applied StemCell Announces Drug Master File Submission to the US FDA for their GMP-Grade iPSC Cell Line
Applied StemCell, an advanced therapeutics CRO/CDMO specializing in iPSCs, gene editing, and small animal models, announced today that it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its ActiCells™ GMP Human Induced Pluripotent Stem Cell (hiPSC) line. This milestone underscores the company’s commitment to empowering scientists to accelerate their cell therapy development by providing high-quality, regulatory-compliant iPSC solutions.
